GSK2336805 + peginterferon alfa-2a + ribavirin

**GSK2336805 + peginterferon alfa-2a + ribavirin** is an investigational combination regimen for the treatment of chronic hepatitis C virus (HCV) infection. **GSK2336805** is a novel, orally bioavailable inhibitor of the HCV nonstructural protein 5A (**NS5A**) with selective activity against HCV genotype 1 and some activity against other genotypes, acting to block viral replication[1][5]. **Peginterferon alfa-2a** is a pegylated recombinant alpha interferon with immunomodulatory and antiviral effects, while **ribavirin** is a nucleoside analogue with broad-spectrum antiviral activity. In clinical studies, this combination demonstrated potent antiviral effects in treatment-naïve HCV-infected subjects, with GSK2336805 showing rapid and significant HCV RNA reduction when used alongside peginterferon alfa-2a and ribavirin[3]. The combination was developed by GSK as a regimen for chronic HCV, particularly genotype 1, and evaluated in Phase II studies[3].